Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy

References

• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• van GestelAWebersCASeverensJLThe long-term outcomes of four alternative treatment strategies for primary open-angle glaucomaActa Ophthalmol2012901203122289192
   PubMed Web of Science ®Google Scholar
• WebersCABeckersHJNuijtsRMSchoutenJSPharmacological management of primary open-angle glaucoma: second-line options and beyondDrugs Aging200825972975918729546
   PubMed Web of Science ®Google Scholar
• BoyleJEGhoshKGieserDKAdamsonsIADorzolamide-Timolol Study GroupA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamideOphthalmology199810510194519519787368
   PubMed Web of Science ®Google Scholar
• AlexanderCLMillerSJAbelSRProstaglandin analog treatment of glaucoma and ocular hypertensionAnn Pharmacother200236350451111895065
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• TsaiJCMcClureCARamosSESchlundtDGPichertJWCompliance barriers in glaucoma: a systematic classificationJ Glaucoma200312539339814520147
   PubMed Web of Science ®Google Scholar
• DjafariFLeskMRHarasymowyczPJDesjardinsDLachaineJDeterminants of adherence to glaucoma medical therapy in a long-term patient populationJ Glaucoma200918323824319295380
   PubMed Web of Science ®Google Scholar
• ChraiSSMakoidMCEriksenSPRobinsonJRDrop size and initial dosing frequency problems of topically applied ophthalmic drugsJ Pharm Sci19746333333384820359
   PubMed Web of Science ®Google Scholar
• HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
   PubMedGoogle Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol2007144453354017686450
   PubMed Web of Science ®Google Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther201329438238923231442
   PubMed Web of Science ®Google Scholar
• KonstasAGQuarantaLRealiniTOverview of the [corrected] travoprost/timolol BAK-free fixed combinationExpert Opin Pharmacother201213575776622360540
   PubMedGoogle Scholar
• KitazawaYSmithPSasakiNKotakiSBaeKIwamotoYTravoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacyEye (Lond)20112591161116921701528
   PubMed Web of Science ®Google Scholar
• SleathBRobinALCovertDByrdJETudorGSvarstadBPatient-reported behavior and problems in using glaucoma medicationsOphthalmology2006113343143616458967
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS) InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol2000130442944011024415
   PubMed Web of Science ®Google Scholar
• BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081
   PubMed Web of Science ®Google Scholar
• MandićZNovak-LausKBojićLSafety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up periodActa Clin Croat201049441141921830452
   PubMed Web of Science ®Google Scholar
• PfeifferNScherzerMLMaierHSafety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapyClin Ophthalmol2010445946620505839
   PubMedGoogle Scholar
• SchumanJSKatzGJLewisRAEfficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertensionAm J Ophthalmol2005140224225016086946
   PubMed Web of Science ®Google Scholar
• ArendKORaberTObservational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in GermanyJ Ocul Pharmacol Ther200824441442018665813
   PubMed Web of Science ®Google Scholar
• CostaVPMoreiraHPaoleraMDde Moraes SilvaMREfficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapyClin Ophthalmol2012669970622654495
   PubMedGoogle Scholar
• KonstasAGMikropoulosDHaidichABNtamposKSStewartWCTwenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucomaBr J Ophthalmol200993448148519019932
   PubMed Web of Science ®Google Scholar
• PachimkulPYuttithamKThoophomP24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertensionJ Med Assoc Thai201194S2S81S8721717884
   PubMedGoogle Scholar
• RheeDJPeaceJHMallickSStudy GroupA study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol20082231331919668722
   PubMedGoogle Scholar
• TopouzisFMelamedSDanesh-MeyerHA 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertensionEur J Ophthalmol200717218319017415690
   PubMed Web of Science ®Google Scholar
• AndradeSCompliance in the real worldValue Health19981317117316674348
   PubMedGoogle Scholar
• OlthoffCMSchoutenJSvan de BorneBWWebersCANoncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based reviewOphthalmology2005112695396115885795
   PubMed Web of Science ®Google Scholar